To identify and deliver high value cancer care, eg delivery of services providing benefits that make their harms and costs worthwhile, for ALL [to highlight and eliminate low value cancer care]
- Identify and advocate for policies that encourage access to high quality cancer services to diagnose and treat their cancer, including screening, vaccinations, tobacco cessation, appropriate genetic testing
- Identify and advocate for policies that protect cancer patients from high cost-sharing requirements
- Steven L. Chang, MD
- Toni K. Choueiri, MD
- Joel E. Goldberg, MD
- Paul L. Nguyen, MD
- Mark A. Preston, MD
- Maxine Sun, MPH
- Bjorn Loppenberg, MD
- Christian Meyer, MD
- Jesse D. Sammon, DO
- Thomas Seisen, MD
- Malte Vetterlein, MD
- Ye Wang, PhD
- The relative effects of CT/MRI imaging use and epidemiological factors on incidence of kidney cancer. Project lead: Maxine Sun
- The association between regional variation in prostate specific antigen-based screening and prostate cancer incidence/mortality. Project lead: Nawar Hanna
- The Impact of Accountable Care Organizations on Cancer Care following the Affordable Care Act. Project lead: Christian Meyer
- Prostate specific antigen screening and prostate cancer incidence following the 2012 United States Preventive Services Task Force recommendations. Project lead: Jesse Sammon
- Patterns of care and adverse events in men treated with abiraterone acetate and/or enzalutamide for advanced prostate cancer. Project lead: Quoc-Dien Trinh
- Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States: A Nationwide Survey Analysis. Abdollah F, Sun M, Sammon JD, Choueiri TK, Menon M, Weissman JS, Trinh QD. JAMA Oncol. 2016 Jan 21. doi: 10.1001/jamaoncol.2015.5871. [Epub ahead of print] No abstract available.
- Targeted Cancer Screening After Solid-Organ Transplantation. Schmid M, Chun FK, Trinh QD. JAMA Oncol. 2016 Jan 7:1-2. doi: 10.1001/jamaoncol.2015.5172. [Epub ahead of print] No abstract available.
- Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. Sun M, Choueiri TK, Hamnvik OR, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD. JAMA Oncol. 2015 Dec 23:1-8. doi: 10.1001/jamaoncol.2015.4917. [Epub ahead of print]
- Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. Sammon JD, Abdollah F, Choueiri TK, Kantoff PW, Nguyen PL, Menon M, Trinh QD. JAMA. 2015 Nov 17;314(19):2077-9. doi: 10.1001/jama.2015.7273. No abstract available.
- Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. Schmid M, Meyer CP, Reznor G, Choueiri TK, Hanske J, Sammon JD, Abdollah F, Chun FK, Kibel AS, Tucker-Seeley RD, Kantoff PW, Lipsitz SR, Menon M, Nguyen PL, Trinh QD. JAMA Oncol. 2016 Jan 1;2(1):85-93. doi: 10.1001/jamaoncol.2015.3384.
- Contemporary nationwide patterns of self-reported prostate-specific antigen screening. Sammon JD, Pucheril D, Diaz M, Kibel AS, Kantoff PW, Menon M, Trinh QD. JAMA Intern Med. 2014 Nov;174(11):1839-41. doi: 10.1001/jamainternmed.2014.4117. No abstract available.
- Study Warns of Alzheimer’s Risk in Some Prostate-Cancer Drugs (The Wall Street Journal)
- Fewer Men Are Getting Prostate Cancer Blood Tests, And That May Not Be a Good Thing (TIME.com)
- Increased Cancer Death Risk After Solid Organ Transplant (Medscape.com)
- Study: Black Men With Prostate Cancer More Likely To Get Worse Care Than White Men (WBUR-FM)
- Robots and Surgeons Equally Safe for Prostatectomy (Medscape.com)
- Robotic Surgery Most Common for Prostate Cancer in the US (Medscape.come)
This page was last modified on 12/27/2016